Which patients most need aluminium testing?

Patients on maintenance dialysis, those with advanced chronic kidney disease exposed to aluminium-containing binders or antacids, and individuals on long-term parenteral nutrition, because impaired clearance or parenteral delivery allows the metal to accumulate.

What clinical problems does aluminium accumulation cause?

Chronically retained aluminium is associated with adynamic (low-turnover) bone disease, a microcytic anaemia resistant to iron, and, at high burden, a progressive dialysis encephalopathy with speech disturbance, myoclonus, and cognitive decline.

How does a normal aluminium result fit with renal function?

A value within the population interval is reassuring in someone with normal kidneys but is read more cautiously in dialysis dependence, where tissue stores can be high despite moderate blood concentrations. Interpretation is always anchored to renal status.

What is a deferoxamine challenge?

Deferoxamine is a chelator that mobilises tissue aluminium into the blood; the rise after a test dose helps estimate body burden when a baseline concentration understates accumulation. A post-challenge sample is interpreted differently from a baseline draw.

Can antacids raise blood aluminium?

Aluminium-containing antacids and phosphate binders add to the absorbed load, which accumulates when renal clearance is reduced. Concurrent citrate markedly increases gastrointestinal absorption, so a full medication history is essential.

Is fasting required for the aluminium blood test?

No fasting is required. For dialysis patients the draw is usually timed before a dialysis session, and the timing of any recent chelation should be recorded for correct interpretation.

How long do results take?

Trace-metal analysis is typically available within about 3–5 business days from specimen receipt, though referral of the assay for ICP-MS measurement can extend the turnaround.

BML-HMT-006heavy metals toxicologyUSA

Aluminum, Blood Test

Q: Why must aluminium be collected in a trace-metal-free tube?

Aluminium is present in ordinary glass, rubber stoppers, needles, and laboratory water, so standard collection equipment contaminates the specimen and can raise the result many-fold. Only a certified trace-metal-free (royal-blue-top) tube and technique give a reliable value.

Blood aluminium measures a non-essential metal that accumulates when renal clearance is impaired or parenteral routes bypass the gut. It is used mainly in dialysis, advanced kidney disease, and long-term parenteral nutrition to detect accumulation linked to bone disease and encephalopathy. Results are valid only from a certified trace-metal-free specimen and interpreted against renal function.

Biomarkers

Blood (whole blood)

Sample

3–5 business days

Turnaround

Fasting

What is the Aluminium (Blood) test?

The Aluminum, Blood Test measures the concentration of aluminium circulating in whole blood, serving as the accessible proxy for a metal that the body neither requires nor handles well once renal clearance is compromised. It is ordered to identify and quantify aluminium exposure in populations where accumulation carries defined clinical consequences — principally patients on maintenance dialysis, those with advanced chronic kidney disease, and individuals receiving prolonged parenteral nutrition in whom intravenous solutions and additives have historically been a source.

Within the heavy-metals work-up, aluminium occupies a narrower niche than lead or mercury: it is rarely part of a general toxic-metal screen in a patient with normal kidneys, where a result is both expected to be low and unusually vulnerable to collection artefact. Instead the clinician reaches for it when the history points to a plausible route of accumulation — reduced renal clearance, parenteral delivery, chronic aluminium-containing antacid or phosphate-binder use — or when otherwise unexplained microcytic anaemia, metabolic bone disease, or a progressive encephalopathy in a dialysis patient raises aluminium as a candidate. Interpretation is anchored to renal status rather than to a single population reference limit.

What does the Aluminium (Blood) test measure?

Al(Aluminium)

Range: Typically <10 µg/L in individuals with normal renal function and no known exposure; whole-blood and serum intervals differ slightly by matrix and platform.Optimal: In dialysis populations many nephrology sources favour maintaining pre-dialysis concentrations below 20 µg/L, with values above 60 µg/L regarded as evidence of significant accumulation warranting intervention.µg/L / nmol/L

Aluminium is a non-essential trivalent metal with no known physiological role. In people with intact kidneys, gastrointestinal absorption is low and the small absorbed fraction is cleared renally, keeping circulating concentrations minimal. When glomerular filtration falls — or when parenteral routes bypass the gut barrier — the metal accumulates, distributing to bone, liver, and the central nervous system, where it binds transferrin and competes with iron and calcium handling.

Circulating aluminium is the practical marker of body burden in patients at risk of accumulation, chiefly those with advanced chronic kidney disease, dialysis dependence, or long-term parenteral nutrition. Concentrations are used to detect exposure, to decide whether a chelation (deferoxamine) challenge is warranted, and to monitor the response to removing an aluminium source. A single value reflects recent circulating metal rather than total tissue stores, so trends and the clinical picture carry more weight than an isolated figure.

Why is the Aluminium (Blood) test ordered?

Surveillance of patients on maintenance haemodialysis or peritoneal dialysis, where accumulated aluminium contributes to adynamic bone disease and dialysis encephalopathy
Evaluation of advanced chronic kidney disease in patients with substantial exposure to aluminium-containing phosphate binders or antacids
Monitoring of patients on long-term parenteral nutrition, in whom intravenous solutions and trace-element additives have been documented aluminium sources
Work-up of unexplained microcytic anaemia unresponsive to iron in a dialysis-dependent patient, where aluminium interferes with haem synthesis
Assessment of progressive cognitive decline, speech disturbance, myoclonus, or seizures in a dialysis patient suggestive of aluminium-related encephalopathy
Investigation of resistant renal osteodystrophy or fractures with low bone turnover where aluminium-related bone disease is in the differential
Selection of candidates for, and monitoring of response to, a deferoxamine chelation challenge when accumulation is suspected
Baseline and periodic testing where occupational or environmental aluminium exposure coincides with impaired renal function

Sample collection and turnaround

Sample type

Blood (whole blood)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

3–5 business days

Collection notes

Phlebotomy at a Quest patient service centre. The specimen MUST be collected into a certified trace-metal-free (royal-blue-top) tube using trace-metal-free collection technique; standard tubes, stoppers, and needles introduce aluminium contamination and invalidate the result. For dialysis patients, draw before a dialysis session and record the timing relative to any deferoxamine administration.

Specimen requirements

Whole blood in a certified trace-metal-free (royal-blue-top, EDTA or dedicated trace-element) tube as specified by the performing laboratory. Avoid contact with glass and non-certified materials throughout collection and transport. Confirm the exact tube, minimum volume, and matrix (whole blood vs serum) with Quest, as these determine the applicable reference interval.

What can affect Aluminium (Blood) results?

elevatesSpecimen contamination from non-trace-metal-free collection tubes or materials

Aluminium is ubiquitous in glass, rubber stoppers, ordinary needles, and even laboratory water, so a specimen drawn or processed in anything other than certified trace-metal-free (royal-blue-top) tubes can be contaminated to many times the true value — the single most important and most common cause of a spuriously high result.

elevatesRenal impairment and dialysis status

Reduced glomerular filtration removes the principal clearance route, so concentrations rise with declining kidney function; results must always be read against renal status rather than a general-population limit.

elevatesAluminium-containing phosphate binders and antacids

Chronic oral intake raises the absorbed load, which accumulates when renal clearance is low; a full medication and over-the-counter history is essential to interpretation.

elevatesCitrate co-administration

Citrate (from citrate-containing medications or anticoagulants) markedly enhances gastrointestinal aluminium absorption, so concurrent intake can sharply increase uptake and measured concentrations in at-risk patients.

variableRecent deferoxamine administration

Chelation mobilises tissue aluminium into the circulation, so a post-challenge rise is expected and interpreted differently from a baseline sample; timing relative to any chelation must be documented.

variableDialysate and water-source aluminium content

Historically, inadequately purified dialysate water was a major exposure; modern reverse-osmosis treatment has reduced this, but a contaminated water source remains a potential confounder in surveillance programmes.

What do Aluminium (Blood) results mean?

Elevated

In a patient with impaired renal function or on dialysis, a raised concentration signals aluminium accumulation and should prompt review of all exposure sources (phosphate binders, antacids, dialysate water, parenteral solutions). Values in the region of 50–60 µg/L and above traditionally justify considering a deferoxamine challenge and evaluation for aluminium-related bone disease or encephalopathy. In a patient with normal kidneys an isolated elevation should first raise suspicion of collection contamination and be confirmed on a correctly drawn trace-metal-free specimen.

Normal

A concentration within the population interval is reassuring in a low-risk patient but is interpreted more cautiously in dialysis dependence, where bone biopsy or a deferoxamine-stimulated value may still be needed if clinical suspicion is high. Blood aluminium correlates only moderately with bone aluminium content.

Reduced

Low or undetectable concentrations are the expected finding in individuals with normal renal function and no unusual exposure and require no action. A low value does not entirely exclude tissue accumulation, since blood reflects recent circulating metal rather than total skeletal stores.

Note: Results are meaningful only when the specimen was collected and handled in certified trace-metal-free equipment; contamination is pervasive and biases upward. Interpretation is inseparable from renal function, exposure history, and the timing of any chelation. Thresholds originate largely from the high-exposure dialysis era and may overstate risk where modern low-aluminium dialysate is used.

Frequently asked questions

Aluminium is present in ordinary glass, rubber stoppers, needles, and laboratory water, so standard collection equipment contaminates the specimen and can raise the result many-fold. Only a certified trace-metal-free (royal-blue-top) tube and technique give a reliable value.

How to access the Aluminium (Blood) test

The Aluminium (Blood) reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

metabolic diabetes

CMP

The Comprehensive Metabolic Panel is a 14-analyte serum chemistry panel simultaneously evaluating renal function (creatinine, BUN, eGFR), hepatic function (ALT, AST, total bilirubin, albumin, total protein), metabolic status (glucose, calcium), and electrolyte-acid-base homeostasis (sodium, potassium, chloride, bicarbonate) from a single fasting serum specimen.

BML-MET-003View reference →

comprehensive panels

CBC with Differential

The Complete Blood Count with Differential quantifies and characterises white blood cells (with 5-part leucocyte differential), red blood cells (with erythrocyte indices including MCV, MCH, MCHC, and RDW), and platelets (with mean platelet volume) from a single EDTA whole blood specimen.

BML-CHP-002View reference →

autoimmune inflammation

CRP

The C-Reactive Protein (CRP) test measures an acute-phase protein produced by the liver in response to inflammatory cytokines, providing a sensitive, rapidly responding marker of inflammation and infection. The standard CRP assay quantifies the higher concentrations of overt inflammation, in contrast to the high-sensitivity (hs-CRP) assay used for cardiovascular risk.

BML-AUT-002View reference →